Navigation Links
Biomet Announces Pricing of Senior Notes
Date:7/25/2012

WARSAW, Ind., July 25, 2012 /PRNewswire/ -- Biomet, Inc. today announced that it has priced its previously announced offering of $550 million aggregate senior notes due 2020, which has been increased to $1.0 billion aggregate principal amount of senior notes due 2020 (the "Senior Notes"), at an issue price of 6.500%.  The Senior Notes will be offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") and to non-U.S. persons in accordance with Regulation S under the Securities Act.  The offering is expected to close on or about August 8, 2012, subject to customary closing conditions.

Biomet intends to use the net proceeds from the offering of the Senior Notes to fund its tender offer for any and all of its outstanding 10⅜% / 11⅛% Senior Toggle Notes due 2017, including related fees expenses, and to purchase, redeem, defease or otherwise acquire or retire its outstanding indebtedness.  The offering is not conditioned on the consummation of the tender offer.

The Senior Notes have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons absent registration under, or an applicable exemption from, the registration requirements of the Securities Act and applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Senior Notes or any other security and shall not constitute an offer, solicitation or sale in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.  Any offers of the Senior Notes will be made only by means of a private offering circular.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by
'/>"/>

SOURCE Biomet, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Biomet Amends Tender Offer of its 10 3/8 %/11 1/8% Series Senior Toggle Notes due 2017 (CUSIP Nos. 090613AD2, 550785AC3 and U55004AB8)
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
(Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
(Date:9/18/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and Drug Administration (FDA) has removed the clinical ... in SWOG,s ongoing Phase 1b/2 clinical trial (S1313). ... drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination ... metastatic pancreatic adenocarcinoma.  The study will resume under ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
(Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
(Date:9/18/2014)... September 18, 2014 Qualis Health, one ... published a white paper, “Advancing Primary Care through ... Information Technology.” , Authors Jeff Hummel, MD, MPH ... guidance to organizations engaged in the work of becoming ... IT can bolster PCMH objectives, such as generating and ...
(Date:9/18/2014)... have developed a new method to study Ebola virus ... Wildlife Conservation Society (WCS)-led research, published today in the ... use of fecal samples from wild great apes to ... virus. This represents a new tool for performing large, ... Ebola virus is studied and improve our understanding of ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
Breaking Medicine News(10 mins):Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2
... small number of teenagers, including non-smokers, are misusing nicotine patches ... could be setting themselves up for health trouble if they ... time or if they use the products to maintain their ... says the students may have lied on the survey. And ...
... to Russian universities has picked up after a six ... Medical Council Act in March 2002. ,This was evident ... universities jointly organized by the Russian Cultural Centre and ... to the organisers, at least 235 students had applied ...
... lower the risk of pre-eclampsia, doctors say. ,Their review ... women can reduce the risk of perinatal death and ... pre-eclampsia or who had chronic hypertension, diabetes or renal ... to 150 mg) //of aspirin were less likely to ...
... to be a better treatment than the antiplatelet drug ... to new research in this week’s issue of the ... black men and women who recently had strokes that ... to blockage of a blood vessel in the brain. ...
... kidney transplant patients reduce their risk of heart attacks, ... been shown to minimize cardiovascular disease in people with ... people with normal cholesterol levels who have other conditions ... Kidney transplant patients have a significantly //higher risk of ...
... who grow slowly in their first year of life ... true regardless of the socioeconomic status of the child's ... by hampered brain development. Biological processes linked to poor ... function with consequent lower //occupational status and income. ...
Cached Medicine News:Health News:Teens Misusing Nicotine-Replacement Products 2Health News:Admission to Russian varsities is looking up 2
... Counter allows the user to quickly and accurately ... for digital counting or manual counting. An optional ... increasing magnification to 3.0X. The adjustable focusing rod ... or lowered. The lens also rotates a full ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
... is a Accelerated Bacterial Enumeration System. Bacterial ... of colonies found by the volume dispensed ... A logarithmically decreasing volume of sample is ... Petri dish in an Archimedes spiral. The ...
... CEQ 8000 is a fully automated ... the capillary array with a patented linear ... sample, applies the voltage program, and analyzes ... review data quality and even customize automated ...
Medicine Products: